A growing disparity in access to the diabetes drug Ozempic between Canada and the United States has exposed structural weaknesses in American pharmaceutical pricing, while underscoring the United Kingdom’s relative advantage within a regulated market. Canadian patients currently pay approximately $150 per month for Ozempic, a fraction of the $900 monthly cost borne by uninsured Americans. This price gap, driven by Canada’s bulk procurement and price controls, has prompted a surge in cross-border prescription traffic and raised questions about the sustainability of the US market-based approach.
For the UK, the situation presents a strategic contrast. The National Health Service negotiates directly with manufacturers, securing Ozempic at a cost of roughly £70 per month per patient. This is achieved through the Voluntary Scheme for Branded Medicines Pricing and Access, which caps overall spending increases and ensures predictable prices. The UK model avoids the ad hoc patchwork of insurance rebates and manufacturer coupons that characterises the American system, where list prices are high but many patients pay considerably less after discounts, but often face administrative hurdles.
The current imbalance stems from the US inability to negotiate drug prices at a federal level, a policy enshrined in the Medicare Modernization Act of 2003. While the Inflation Reduction Act of 2022 introduced limited negotiation for certain high-cost drugs, Ozempic is not currently eligible. In Canada, the Patented Medicine Prices Review Board enforces price ceilings, and provincial drug plans leverage bargaining power. The result is a dual market: Canadians benefit from state-mediated pricing, while Americans depend on employer-sponsored insurance and pharmacy benefit managers, a system that favours list price inflation.
For British policymakers, the Ozempic case reinforces the merits of centralised procurement. However, tensions remain. The UK’s departure from the EU required a new trade deal that did not include pharmaceutical pricing commitments, and the current system depends on voluntary industry cooperation. The Voluntary Scheme expires in 2024, and renegotiation may test industry willingness to continue price restraint given global demand for GLP-1 agonists like Ozempic.
Diplomatically, the UK has positioned itself as a bridge between the US and Canadian approaches. Trade negotiations with Washington have not addressed drug pricing directly, but the disparity has become a talking point among UK trade officials, who note that British companies enjoy access to the Canadian market under the Comprehensive Economic and Trade Agreement, while American firms face no such price constraints in the UK. This asymmetry could become a bargaining chip in future trade discussions.
Domestically, the NHS has already seen increased demand for Ozempic, not just for diabetes but for off-label weight loss, prompting supply concerns. The Northern Ireland Protocol has added complexity, with separate regulatory routes for the region. Meanwhile, the US Food and Drug Administration has warned of counterfeit Ozempic entering the market, a risk that a single-payer system with central purchasing can more easily mitigate.
The broader implication is that pharmaceutical pricing remains a zone of geopolitical friction. As diabetes and obesity rates rise globally, the ability to provide affordable access to effective treatments will shape public health outcomes and national competitiveness. The UK’s model, while not without flaws, offers a template that balances industry innovation with population health. For now, the Ozempic trade gap between Canada and the US serves as a reminder that market structures have direct consequences for patients, and that Britain’s institutional approach provides a measure of stability that its transatlantic partners lack.
